Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solid tumor antigen refers collectively to molecular markers exploited as therapeutic targets across diverse types of non-blood cancers. Most current clinical strategies focus on TAAs rather than truly unique TSAs due to their broader applicability despite increased safety concerns stemming from shared expression with some healthy tissues.
Targeted cell killing via immune response or cytotoxic drug delivery
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solid Tumor Antigen (STA).